ICU卒中患者与其他危重患者的长期死亡率比较
该研究基于荷兰国家重症监护评估数据库2010至2015年收治的370,386例成人ICU患者,其中卒中患者7,046例(1.9%),包括缺血性卒中4,072例和脑出血2,974例,随访至2017年2月。缺血性卒中30天死亡率为31%,脑出血为42%。存活超过30天后的卒中患者后续生存优于脓毒症或重症社区获得性肺炎患者。入ICU后存活超过3个月,多变量Cox回归显示缺血性卒中随访至3年的病例组合校正风险比低于脓毒症(1.21;95%CI 1.06-1.36)和重症社区获得性肺炎(1.57;95%CI 1.39-1.77),脑出血同样低于上述两组(分别为1.14;95%CI 0.98-1.33和1.49;95%CI 1.28-1.73)。
要点
- ICU卒中患者短期死亡率高:缺血性卒中30天死亡率31%,脑出血42%。
- 存活超过30天后,卒中患者的后续生存优于脓毒症或重症社区获得性肺炎患者。
- 入ICU后存活超过3个月,缺血性卒中3年内死亡风险低于脓毒症(校正HR 1.21;95%CI 1.06-1.36)。
- 入ICU后存活超过3个月,缺血性卒中3年内死亡风险低于重症社区获得性肺炎(校正HR 1.57;95%CI 1.39-1.77)。
- 脑出血存活超过3个月后3年内死亡风险低于脓毒症(校正HR 1.14;95%CI 0.98-1.33)和重症社区获得性肺炎(校正HR 1.49;95%CI 1.28-1.73)。
适用人群与场景
- 2010年至2015年收治于荷兰国家重症监护评估数据库所有ICU的成人患者,随访至2017年2月。
- 纳入370,386例ICU患者,其中卒中患者7,046例(1.9%),包括缺血性卒中4,072例和脑出血2,974例。
研究设计与关键结果
- 研究类型为观察性队列研究,样本量370,386例,人群为荷兰所有参与国家重症监护评估数据库的ICU成人患者,无干预。
- 卒中患者占全部ICU患者的1.9%(7,046例),其中缺血性卒中4,072例,脑出血2,974例。
- 缺血性卒中30天死亡率为31%,脑出血30天死亡率为42%。
- 缺血性卒中和脑出血患者的生存曲线梯度在较长随访期趋于稳定。
- 采用左截断法评估入ICU后死亡风险随最小生存期延长而变化。
- 存活超过30天的ICU卒中患者后续生存优于因脓毒症或重症社区获得性肺炎入ICU的患者。
- 入ICU后存活超过3个月,多变量Cox回归显示随访至3年的病例组合校正风险比:缺血性卒中 vs 脓毒症为1.21(95%CI 1.06-1.36),缺血性卒中 vs 重症社区获得性肺炎为1.57(95%CI 1.39-1.77)。
- 入ICU后存活超过3个月,脑出血 vs 脓毒症校正风险比为1.14(95%CI 0.98-1.33),脑出血 vs 重症社区获得性肺炎为1.49(95%CI 1.28-1.73)。
证据类型、等级与局限
- 证据类型:观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于ICU收治的缺血性卒中和脑出血患者,短期死亡风险高(30天死亡率分别为31%和42%),但存活超过30天后后续生存优于脓毒症或重症社区获得性肺炎患者。
- 入ICU后存活超过3个月的卒中患者,其3年内死亡风险低于脓毒症和重症社区获得性肺炎患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Assessment of all-cause mortality of intracerebral hemorrhage and ischemic stroke patients admitted to the ICU and comparison to the mortality of other critically ill ICU patients classified into six other diagnostic subgroups and the general Dutch population.
DESIGN: Observational cohort study.
SETTING: All ICUs participating in the Dutch National Intensive Care Evaluation database.
PATIENTS: All adult patients admitted to these ICUs between 2010 and 2015; patients were followed until February 2017.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Of all 370,386 included ICU patients, 7,046 (1.9%) were stroke patients, 4,072 with ischemic stroke, and 2,974 with intracerebral hemorrhage. Short-term mortality in ICU-admitted stroke patients was high with 30 days mortality of 31% in ischemic stroke and 42% in intracerebral hemorrhage. In the longer term, the survival curve gradient among ischemic stroke and intracerebral hemorrhage patients stabilized. The gradual alteration of mortality risk after ICU admission was assessed using left-truncation with increasing minimum survival period. ICU-admitted stroke patients who survive the first 30 days after suffering from a stroke had a favorable subsequent survival compared with other diseases necessitating ICU admission such as patients admitted due to sepsis or severe community-acquired pneumonia. After having survived the first 3 months after ICU admission, multivariable Cox regression analyses showed that case-mix adjusted hazard ratios during the follow-up period of up to 3 years were lower in ischemic stroke compared with sepsis (adjusted hazard ratio, 1.21; 95% CI, 1.06-1.36) and severe community-acquired pneumonia (adjusted hazard ratio, 1.57; 95% CI, 1.39-1.77) and in intracerebral hemorrhage patients compared with these groups (adjusted hazard ratio, 1.14; 95% CI, 0.98-1.33 and adjusted hazard ratio, 1.49; 95% CI, 1.28-1.73).
CONCLUSIONS: Stroke patients who need intensive care treatment have a high short-term mortality risk, but this alters favorably with increasing duration of survival time after ICU admission in patients with both ischemic stroke and intracerebral hemorrhage, especially compared with other populations of critically ill patients such as sepsis or severe community-acquired pneumonia patients.
参考来源
- van Valburg MK, Termorshuizen F, Brinkman S, et al. Long-Term Mortality Among ICU Patients With Stroke Compared With Other Critically Ill Patients. Crit Care Med. 2020. PMID: 32931193. doi:10.1097/CCM.0000000000004492
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。